Fluad
Biological
Seqirus USA Inc
Total Payments
$2.8M
Transactions
4,104
Doctors
3,362
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $31,799 | 1,508 | 1,399 |
| 2020 | $6,005 | 342 | 335 |
| 2019 | $45,099 | 953 | 862 |
| 2018 | $2.7M | 1,110 | 922 |
| 2017 | $2,752 | 191 | 190 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 119 | 97.5% |
| Food and Beverage | $68,795 | 3,951 | 2.4% |
| Education | $508.47 | 33 | 0.0% |
| Honoraria | $500.00 | 1 | 0.0% |
Payments by Type
Research
$2.8M
119 transactions
General
$69,803
3,985 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Adjuvanted influenza Vaccination and Morbidity and Mortaliy in US Nursing Homes | Seqirus USA Inc | $1.7M | 0 |
| This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine aTIV-1, Fluad, and versus an adjuvanted trivalent influenza vaccine aTIV-2, containing the alternate B strain | Seqirus USA Inc | $1.0M | 0 |
| A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above | Seqirus USA Inc | $30,082 | 0 |
| A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults 65 Years of Age | Seqirus USA Inc | $9,600 | 0 |
| A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children 6 to 72 Months of Age. | Seqirus USA Inc | $250.00 | 0 |
Top Doctors Receiving Payments for Fluad — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Milwaukee, WI | $36.56 | 2 |
| , PA-C | Physician Assistant | Colorado Springs, CO | $36.40 | 2 |
| , PA-C | Medical | Colorado Springs, CO | $36.40 | 2 |
| , MD | Pediatrics | Houston, TX | $36.35 | 2 |
| , MD | Internal Medicine | Rochester, NY | $36.33 | 2 |
| , MD | Internal Medicine | Rochester, NY | $36.33 | 2 |
| , MD | Family Medicine | Vero Beach, FL | $36.32 | 2 |
| , M.D | Internal Medicine | Rochester, NY | $36.32 | 2 |
| , MD | Internal Medicine | New York, NY | $36.30 | 2 |
| , MD | Dermatology | Port Orchard, WA | $36.21 | 2 |
| , M. D | Internal Medicine | Highland, IN | $36.19 | 2 |
| , M.D | Specialist | Watervliet, NY | $36.07 | 2 |
| , MD | Surgery | Oxon Hill, MD | $36.04 | 2 |
| , M.D | Specialist | Beverly Hills, CA | $36.03 | 2 |
| , M.D | Family Medicine | Randolph, NY | $36.01 | 2 |
| , MD | Family Medicine | Slingerlands, NY | $36.00 | 2 |
| , FNP-C | Family | O Fallon, MO | $35.99 | 1 |
| , FNP-C | Family | O Fallon, MO | $35.99 | 1 |
| , MD | Family Medicine | Monterey, CA | $35.96 | 2 |
| , MD | Internal Medicine | Newark, DE | $35.83 | 2 |
| , D.O | Internal Medicine | Williamsville, NY | $35.79 | 2 |
| , D.O | Family Medicine | Williamsville, NY | $35.79 | 2 |
| , MD | Internal Medicine | Indiana, PA | $35.67 | 2 |
| , D.O | Internal Medicine | Indiana, PA | $35.66 | 2 |
| , M.D | Internal Medicine | Pittsburgh, PA | $35.62 | 2 |
Ad
Manufacturing Companies
- Seqirus USA Inc $2.8M
Product Information
- Type Biological
- Total Payments $2.8M
- Total Doctors 3,362
- Transactions 4,104
About Fluad
Fluad is a biological associated with $2.8M in payments to 3,362 healthcare providers, recorded across 4,104 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2024. In 2024, $31,799 was paid across 1,508 transactions to 1,399 doctors.
The most common payment nature for Fluad is "Unspecified" ($2.8M, 97.5% of total).
Fluad is associated with 5 research studies, including "Adjuvanted influenza Vaccination and Morbidity and Mortaliy in US Nursing Homes" ($1.7M).